Alendronic Acid

Alendronic Acid

SCHEMBL140619

NCCCC(O)(P(=O)(O)O)P(=O)(O)O.[NaH].[NaH]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FDPS

The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 17/20 0.95
PDE3A Q14432 3/20 0.95
LMNA P02545 2/20 0.70
ADRB3 P13945 1/20 0.70
PDE4D Q08499 1/20 0.70
GGPS1 O95749 7/20 0.56
CYP3A4 P08684 1/20 0.42
NFKB1 P19838 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
AGTR1 P30556 1/20 0.40
OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alendronic Acid SCHEMBL140618 1.00 FDPS (0.95) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL6856868 1.00 FDPS (0.95) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL1115700 1.00 FDPS (0.95) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL5974139 1.00 FDPS (0.95) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL5973509 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL1130855 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL192828 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL1268399 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL579003 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL7831398 0.98 FDPS (0.91) FDPSPDE3ALMNAADRB3PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2864 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4324492-B1 MULTIFUNCTIONAL, HYDROGEL HYBRID MATERIAL, METHOD OF ITS PREPARATION AND USE IN THE TREATMENT OF BONE LOSSES UNIV JAGIELLONSKI (PL) 2026-03-04 EP claimed
US-20250381141-A1 Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof POLITECHNIKA WARSZAWSKA (PL) 2025-12-18 US claimed
US-20250375395-A1 TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG CORIUM INTERNATIONAL, INC. 2025-12-11 US claimed
WO-2025133965-A2 RELEASE SYSTEM FOR THE TOPICAL OR INTRA-ARTICULAR ADMINISTRATION OF DRUGS FIDIA FARMACEUTICI S.P.A. (IT) 2025-06-26 WO claimed
CN-119931931-A ALPL+ PDGFD +periosteum stem cell, preparation method and application thereof 北京大学口腔医学院 2025-05-06 CN claimed
CN-119868587-A NMN-loaded nanoparticle of stem cell exosome stimulated by alendronate sodium and application thereof 湖州科元生物科技有限公司 2025-04-25 CN claimed
CN-119701019-A Bone metastasis diagnosis and treatment integrated carbon-based nano platform and preparation method and application thereof 山西省人民医院 2025-03-28 CN claimed
EP-4204028-B1 MULTIFUNCTIONAL, HYDROGEL HYBRID MATERIAL, THE METHOD OF ITS PREPARATION AND THE USE IN THE TREATMENT OF BONE LOSSES UNIV JAGIELLONSKI (PL) 2024-10-09 EP claimed
EP-4426268-A1 FORMULATION OF LECITHIN-MODIFIED CALCIUM PHOSPHATE NANOPARTICLES WITH AN ENHANCED CELLAR UPTAKE AS A CARRIER FOR BISPHOSPHONATES AND A METHOD OF PREPARING THEREOF POLITECHNIKA WARSZAWSKA (PL) 2024-09-11 EP claimed
CN-118541142-A Formulations of lecithin-modified calcium phosphate nanoparticles with enhanced cellular uptake as carriers for bisphosphonates and methods of making the same 华沙理工大学 2024-08-23 CN claimed
EP-1128813-A1 AN INHALATION SYSTEM Pilkiewicz, Frank G. (US) 2001-09-05 EP claimed
US-6281381-B1 CRYSTAL STRUCTURE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2001-08-28 US claimed
WO-2000027359-A1 AN INHALATION SYSTEM PILKIEWICZ FRANK G (US) 2000-05-18 WO claimed
WO-2000000179-A1 SOLID DISPERSED PREPARATION OF POORLY WATER-SOLUBLE DRUG CONTAINING OIL, FATTY ACID OR MIXTURES THEREOF WON JIN BIOPHARMA CO., LTD. (KR) 2000-01-06 WO claimed
US-6008206-A A DRUG DELIVERY BY IONTOPHORETIC ADMINISTRATION FOR TREATING BONE DISORDER MERCK & CO., INC. (US) 1999-12-28 US claimed
US-5958908-A Sodium alendronate preparation for local administration MERCK & CO., INC. (US) 1999-09-28 US claimed
EP-0939624-A1 EFFERVESCENT BISPHOSPHONATE FORMULATION Merck & Co., Inc. (US) 1999-09-08 EP claimed
EP-0831756-A1 BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES Merck & Co., Inc. (US) 1998-04-01 EP claimed
WO-1997044017-A1 EFFERVESCENT BISPHOSPHONATE FORMULATION MERCK & CO., INC. (US) 1997-11-27 WO claimed
WO-1996039107-A1 BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES MERCK & CO., INC. (US) 1996-12-12 WO claimed